FDA Fast-Tracks Psilocybin and Methylone With Priority Review Vouchers

What happened: In April 2026, the FDA issued National Priority Review Vouchers to three companies developing psychedelic-based medicines:

1. Psilocybin for treatment-resistant depression (TRD) — Compass Pathways, which is running two concurrent Phase 3 clinical trials.
2. Psilocybin for major depressive disorder (MDD) — a second psilocybin-focused company.
3. Methylone for PTSD — methylone is a synthetic empathogen pharmacologically similar to MDMA but with a distinct regulatory profile.

Priority Review Vouchers allow recipients to accelerate FDA review timelines by roughly six months — and, critically, can be sold to other companies for hundreds of millions of dollars, making them a meaningful signal of FDA’s institutional commitment to the space.

Context: The FDA declined the first MDMA-assisted therapy New Drug Application in August 2024, citing concerns about the trial design and asking Lykos Therapeutics to run a new Phase 3. That decision slowed the MDMA timeline substantially. The psychedelic field’s response: diversify. Psilocybin and methylone developers have been explicitly designing trials to avoid the methodological critiques that sank the MDMA application.

Bloomberg’s oversight concern: A May 4 Bloomberg op-ed argues that expedited review timelines for psychedelics — which require highly controlled therapeutic settings and trained facilitators — create risks if safety and implementation standards aren’t established concurrently with approval.

State-level momentum: Texas, despite its conservative political profile, has been actively lobbying for psychedelic therapy access, citing veteran suicide rates. Several states with existing psilocybin programs (Oregon, Colorado) are watching the FDA timeline closely — federal scheduling determines what is legally possible statewide.

Addiction applications: While the current FDA pipeline focuses on depression and PTSD, psilocybin’s most compelling addiction applications — studied at Johns Hopkins and NYU — include alcohol use disorder and tobacco cessation. Compass Pathways’ approval, if it comes, would open the door for AUD and OUD indications in subsequent trials.

Why This Matters for People in Recovery

Psychedelic-assisted therapy is not yet available through standard treatment channels — but the regulatory path is now moving faster than at any point in the modern clinical era. For people with treatment-resistant depression, PTSD, or alcohol use disorder who have not responded to conventional care, this timeline matters.

Explore psychedelic-assisted therapy for addiction → | Find treatment options →